期刊文献+

乳腺癌内分泌治疗的依从性研究及影响因素分析 被引量:5

下载PDF
导出
摘要 目的:了解激素受体(HR)阳性乳腺癌患者内分泌治疗的药物依从性情况及影响因素。方法:回顾分析199例符合内分泌治疗要求的HR阳性乳腺癌患者的临床资料,采用自制量表进行随访、评价依从性、分析影响因素。结果:HR阳性患者占同期乳癌患者总数的73.2%,随访成功188人,服药依从性好的113人(60.1%)。患者年龄、生活自理能力、经济状况、疾病认知、病情变化及是否定期随访复查等是影响依从性好坏的因素。结论:患者内分泌治疗的依从性有待提高,需注重与患者有效沟通、提高医药报销比例、加强健康宣教、开展多种形式的随访与纳入慢病全程管理范畴。
出处 《中国民康医学》 2014年第15期33-36,共4页 Medical Journal of Chinese People’s Health
  • 相关文献

参考文献15

  • 1佘晓佳,刘琳,宋淑芬,秦旗,徐莉,崔媛,王先明.乳腺癌内分泌治疗期患者依从性及健康需求调查[J].深圳中西医结合杂志,2011,21(4):255-256. 被引量:4
  • 2DanilakM.,C.R.Chambers.Adherencetoadjuvantendocrinetherapyinwomenwithbreastcancer[J].JOncolPharmPract,2013,19(2):105-110.
  • 3AtkinsL,L.Fallowfield.Intentionalandnon-intentionalnon-adherencetomedicationamongstbreastcancerpatients[J].EurJCancer,2006,42(14):2271-2276.
  • 4HadjiP.Improvingcomplianceandpersistencetoadjuvanttamoxifenandaromataseinhibitortherapy[J].CritRevOncolHematol.2010,73(2):156-166.
  • 5ZillerV.Adherencetoadjuvantendocrinetherapyinpostmenopausalwomenwithbreastcancer[J].AnnOncol,2009,20(3):431-436.
  • 6HershmanDL.Earlydiscontinuationandnonadherencetoadjuvanthormonaltherapyinacohortof8,769early-stagebreastcancerpatients[J].JClinOncol,2010,28(27):4120-4128.
  • 7BarronTI.DiseaseSite:BreastDisease:Earlydiscontinuationoftamoxifen:ALessonforoncologists[J].Cancer,2007,109(5):832-839.
  • 8GuthU.Complianceandpersistenceofendocrineadjuvantbreastcancertherapy[J].BreastCancerResTreat,2012,131(2):491-499.
  • 9MakubateB.Cohortstudyofadherencetoadjuvantendocrinetherapy,breastcancerrecurrenceandmortality[J].BrJCancer,2013,108(7):1515-1524.
  • 10许卫华,王奇,梁伟雄.问卷或量表在病人依从性测量中的应用[J].中国慢性病预防与控制,2007,15(4):403-405. 被引量:112

二级参考文献43

  • 1毛雪琴,潘芳,孙靖中,江虹,张洪静.围术期乳腺癌病人情绪的观察[J].中华护理杂志,2004,39(6):422-424. 被引量:119
  • 2Beatson GT.On the treatment of inoperable cases of carcinoma of the mamma-suggestion for a new method of treatment[J].Lancet,1896,2:162-170.
  • 3Hammond ME,Hayes DF,Dowsett M,et al.American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].J Clin Oncol,2010,28:2784-2795.
  • 4Paridaens R,Dirix L.Mature results of a randomized phaseⅡmulticenter study of exemestane versus tamoxifen as first-line hormonetherapy for postmenopausal women with metastatic breast cancer[J].Ann Oncol,2003,14:1391-1398.
  • 5Early Breast Cancer Trialists' Collaborative Group:Ovarian ablation in early breast cancer:overview of the randomised trials[J].Lancet,1996,348:1189-1196.
  • 6Davidson NE,O'Neill AM,Vukov AM,et al.Chemoendocrine therapy for premenopausal women with axillary lymph node-positive,steroid hormone receptor-positive breastcancer:results from INT 0101 (E5188)[J].J Clin Oncol,2005,23:5973-5982.
  • 7Howell A,Cuzick J,Baum M,et al.ATAC Trialists' Group:Results of the ATAC (Arimidex,Tamoxifen,Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer[J].Lancet,2005,365:60-62.
  • 8Breast International Group (BIG) 1-98 Collaborative Group,Thurlimann B,Keshaviah A,et al.A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer[J].N Engl J Med,2005,353:2747-2757.
  • 9Coombes RC,Hall E,Gibson LJ,et al.Intergroup Exemestane Study:A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer[J].N Engl J Med,2004,350:1081-1092.
  • 10Boccardo F,Rubagotti A,Puntoni M,et al.Switching to anastrozole versus continued tamoxifen treatment of early breast cancer:preliminary results of the Italian Tamoxifen Anastrozole Trial[J].J Clin Oncol,2005,23:5138-5147.

共引文献116

同被引文献95

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部